Asterias Bio gets $14.3M award from CIRM

|By:, SA News Editor

BioTime (BTX +7.3%) subsidiary Asterias Biotherapeutics receives a $14.3M strategic partnership award from the California Institute for Regenerative Medicine (CIRM). The award supports the company's Phase 1/2 dose escalation trial of AST-OPC1 in cervical spinal cord injury.